MarketPulse

glucagon/GLP-1 dual agonist

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Boehringer Ingelheim's Dual-Action Obesity Drug Survodutide Shows 16.6% Weight Loss

Boehringer Ingelheim's survodutide achieved 16.6% average weight loss in Phase III trials, with 85.1% of patients hitting ≥5% reduction targets, supporting obesity and MASH treatment potential.
ZLDPYclinical trial resultsweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Boehringer's Obesity Drug Survodutide Posts Strong Phase 3 Results, Boosting Zealand Pharma

Boehringer's survodutide shows 16.6% weight loss in Phase 3 trial, benefiting Zealand Pharma with EUR 315M in potential milestone payments and ongoing royalties.
ZLDPYPhase 3 trialweight loss